文献速递妇科产科

子宫内膜癌林奇综合征两种筛查方法的性能评估:一项临床试验

Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial.
PubMed 文献 · Gynecol Oncol · 2021-10-21

该研究纳入200例子宫内膜癌患者,在常规诊疗中同时进行简短家族史问卷(bFHQ)和错配修复(MMR)蛋白免疫组化(IHC)筛查,并以基因检测为金标准。基因检测发现8例林奇综合征(患病率4%),bFHQ检出5/8例(62.5%),IHC检出6或7/8例(平均75%或87.5%);bFHQ和IHC的特异性分别为56.8%和79.8%。研究提示bFHQ敏感性有限,IHC性能在文献报道范围内但不足以指导决策。

要点

  • 在子宫内膜癌人群中,bFHQ对林奇综合征的敏感性为62.5%(5/8),特异性为56.8%。
  • IHC对林奇综合征的敏感性为75%或87.5%(取决于结果判读),特异性为79.8%。
  • 基因检测确定的林奇综合征患病率为4%(8/200),两种筛查方法均未完全检出。

核心结论

  • bFHQ在子宫内膜癌人群中敏感性有限(62.5%),IHC敏感性为75%或87.5%,特异性分别为56.8%和79.8%。
  • IHC作为林奇综合征筛查的性能在文献报道范围内,但不足以支持或反对继续将其用作筛查工具。

研究设计与样本

  • 前瞻性临床试验,在常规诊疗中招募200例子宫内膜癌女性。
  • 所有参与者完成bFHQ并接受林奇综合征相关基因的基因检测作为参考标准。
  • 独立进行MMR蛋白IHC检测以筛查疑似林奇综合征病例。

主要发现

  • 基因检测在200例中检出8例林奇综合征,患病率4%。
  • bFHQ检出5/8例林奇综合征,敏感性62.5%(CI:31.5%-87.6%),特异性56.8%(CI:49.8%-63.7%)。
  • IHC检出6或7/8例林奇综合征,敏感性平均75%或87.5%(取决于结果判读),特异性79.8%(CI:73.6%-85.1%)。

关键数值与推荐

  • bFHQ敏感性62.5%(CI:31.5%-87.6%),特异性56.8%(CI:49.8%-63.7%)。
  • IHC敏感性平均75%或87.5%(取决于判读),特异性79.8%(CI:73.6%-85.1%)。
  • 林奇综合征患病率4%(8/200)。

临床怎么用

  • bFHQ单独用于林奇综合征筛查可能漏诊较多病例,需谨慎解读阴性结果。
  • IHC筛查性能在文献报道范围内,但当前证据不足以支持或反对继续使用。
  • 临床决策应结合基因检测等进一步评估,不宜仅依赖bFHQ或IHC筛查结果。

局限性

  • 样本量较小(200例),林奇综合征病例仅8例,敏感性估计的置信区间较宽。
  • bFHQ的性能仅在原作者报道之外首次评估,结果可能受人群和医疗系统差异影响。
  • IHC敏感性因结果判读不同而存在差异,判读标准可能影响性能评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: Published data on the performance of the immunohistochemistry (IHC) test for mismatch repair (MMR) protein expression to detect Lynch syndrome (LS) index cases suggests it is highly variable; its performance in our system was unknown. Moreover, a brief family history questionnaire (bFHQ) developed by Eiriksson and colleagues in Canada demonstrated 100% sensitivity for LS case identification thus was of interest to us, but its performance outside of its original setting was unknown. Determination of the performance of these tests requires complete LS case identification in the testing population. METHODS: Two hundred women were recruited during routine care for endometrial cancer (EC) to administer the bFHQ and perform genetic testing for the LS genes. Independently, the IHC test was performed to screen for presumptive LS cases. We determined the sensitivity, specificity, and positive and negative predictive values of the bFHQ and IHC test as well as simulating outcomes of the complete protocols. RESULTS: Genetic testing all participants identified 8 cases of LS out of 200 (4% prevalence), the bFHQ identified 5 of 8 of these cases (62.5%, CI: 31.5%-87.6%), and the IHC test identified 6 or 7 of 8 cases (mean of 75% or 87.5%) depending on interpretation of test results. The specificities of the bFHQ and IHC test were 56.8% (CI: 49.8%-63.7%) and 79.8% (CI: 73.6%-85.1%), respectively. CONCLUSIONS: This study is the first, to our knowledge, to test the effectiveness of the bFHQ in an EC population since its original reporting; our results are consistent with many reports of the challenges of collecting family health history. The performance of the IHC test as a screen falls within ranges reported in the literature but do not provide the confidence to drive a decision for or against continued use of this test as a LS screen.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gudgeon JM, Wallentine JC, Bonham EM, et al. Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial. Gynecol Oncol. 2021. PMID: 34689999. doi:10.1016/j.ygyno.2021.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。